MX2010001196A - Heterociclicos fusionados. - Google Patents

Heterociclicos fusionados.

Info

Publication number
MX2010001196A
MX2010001196A MX2010001196A MX2010001196A MX2010001196A MX 2010001196 A MX2010001196 A MX 2010001196A MX 2010001196 A MX2010001196 A MX 2010001196A MX 2010001196 A MX2010001196 A MX 2010001196A MX 2010001196 A MX2010001196 A MX 2010001196A
Authority
MX
Mexico
Prior art keywords
substituted
unsubstituted
sub
member selected
group
Prior art date
Application number
MX2010001196A
Other languages
English (en)
Inventor
Qun Kevin Fang
Michele L R Heffernan
Robert J Foglesong
Seth C Hopkins
Cyprian O Ogbu
Mustapha Soukri
Kerry L Spear
James M Dorsey
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of MX2010001196A publication Critical patent/MX2010001196A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a heterociclos fusionados que tienen la fórmula: en la cual, R' es un elemento seleccionado a partir del grupo que consiste de H, arilalquilo sustituido o insustituido y heteroarilalquilo sustituido o insustituido. R2 es un elemento seleccionado a partir del grupo que consiste de H, alquenilo sustituido o insustituido, arilalquilo sustituido o insustituido y heteroarilalquilo sustituido o insustituido. R3 es un elemento seleccionado a partir del grupo que consiste de H, alquilo C1-C6 sustituido o insustituido, arilalquilo sustituido o insustituido y heteroarilalquilo sustituido o insustituido. R4 es un elemento seleccionado a partir de OH y OX, en el cual, X es un ión positivo, el cual es un porciones de arilalquilo sustituido o insustituido o heteroarilalquilo sustituido o insustituido, tienen la fórmula: en la cual, Ar es un elemento seleccionado a partir del grupo que consiste de arilo sustituido o insustituido o heteroarilo sustituido o insustituido. El índice n es un número entero desde 1 hasta 4. Fórmulas A, B.
MX2010001196A 2007-08-03 2008-07-30 Heterociclicos fusionados. MX2010001196A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/833,903 US7579370B2 (en) 2006-06-30 2007-08-03 Fused heterocycles
PCT/US2008/071642 WO2009020814A2 (en) 2007-08-03 2008-07-30 Fused heterocycles

Publications (1)

Publication Number Publication Date
MX2010001196A true MX2010001196A (es) 2010-03-04

Family

ID=40342283

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001196A MX2010001196A (es) 2007-08-03 2008-07-30 Heterociclicos fusionados.

Country Status (11)

Country Link
US (3) US7579370B2 (es)
EP (1) EP2173170A4 (es)
JP (1) JP2010535783A (es)
KR (1) KR20100047276A (es)
CN (1) CN101820760A (es)
AU (1) AU2008284086A1 (es)
BR (1) BRPI0815077A2 (es)
CA (1) CA2695431A1 (es)
MX (1) MX2010001196A (es)
RU (1) RU2010107684A (es)
WO (1) WO2009020814A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200605383B (en) * 2003-12-29 2008-06-25 Sepracor Inc Pyrrole and pyrazole daao inhibitors
WO2007006003A2 (en) 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
WO2007081542A2 (en) * 2006-01-06 2007-07-19 Sepracor Inc. Tetralone-based monoamine reuptake inhibitors
RU2430913C2 (ru) 2006-01-06 2011-10-10 Сепракор Инк. Циклоалкиламины в качестве ингибиторов повторного поглощения моноамина
DK2013835T3 (en) 2006-03-31 2015-12-14 Sunovion Pharmaceuticals Inc Preparation of chiral amides and AMINES
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
US20080082066A1 (en) * 2006-10-02 2008-04-03 Weyerhaeuser Co. Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks
EP2298772A1 (en) 2006-10-18 2011-03-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
CA2676432A1 (en) * 2007-01-18 2008-07-24 Sepracor, Inc. Inhibitors of d-amino acid oxidase
BRPI0811639A2 (pt) 2007-05-31 2014-09-30 Sepracor Inc Cicloaquilaminas fenil substituídas como inibidores da recaptação de monoamina
US20100120740A1 (en) * 2008-08-07 2010-05-13 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
WO2011017634A2 (en) * 2009-08-07 2011-02-10 Sepracore Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
JP6169492B2 (ja) 2011-11-15 2017-07-26 武田薬品工業株式会社 ジヒドロキシ芳香族へテロ環化合物
WO2014025993A1 (en) 2012-08-08 2014-02-13 The Johns Hopkins University Inhibitors of d-amino acid oxidase
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
GB201222711D0 (en) 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
US9647338B2 (en) * 2013-03-11 2017-05-09 Pulse Finland Oy Coupled antenna structure and methods
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US10293571B2 (en) * 2014-05-20 2019-05-21 Euro Trade Flooring, S.L. Multilayer lining plate for horizontal support
WO2019043635A1 (en) 2017-09-01 2019-03-07 Richter Gedeon Nyrt. COMPOUNDS INHIBITING THE ACTIVITY OF D-AMINO ACID OXIDASE

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA817261B (en) * 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
US4540690A (en) * 1982-02-09 1985-09-10 The Upjohn Company 2-(Phenylmethylene)cycloalkylamines and -azetidines
DE3431541A1 (de) * 1984-08-28 1986-03-06 Hoechst Ag, 6230 Frankfurt Cis,endo-2-azabicycloalkan-3-carbonsaeure-derivate, verfahren zu deren herstellung, deren verwendung sowie zwischenprodukte bei deren herstellung
US4738709A (en) * 1985-01-10 1988-04-19 Ppg Industries, Inc. Herbicidally active substituted benzisoxazoles
US4751231A (en) * 1987-09-16 1988-06-14 Merck & Co., Inc. Substituted thieno[2,3-b]pyrrole-5-sulfonamides as antiglaucoma agents
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
US4960786A (en) * 1989-04-24 1990-10-02 Merrell Dow Pharmaceuticals Inc. Excitatory amino acid antagonists
US5137910A (en) * 1989-05-05 1992-08-11 C.D. Searle & Co. Compositions containing indole-2-carboxylate compounds for treatment of CNS disorders
ES2123500T3 (es) * 1989-05-31 1999-01-16 Upjohn Co Derivados de 8-heterociclil-2-aminotetralina activos sobre el sistema nervioso central.
US5456919A (en) * 1989-12-29 1995-10-10 Bristol-Myers Squibb Company Capsule and caplet combination
US5284862A (en) * 1991-03-18 1994-02-08 Warner-Lambert Company Derivatives of 2-carboxyindoles having pharmaceutical activity
GB9208492D0 (en) * 1992-04-16 1992-06-03 Glaxo Spa Heterocyclic compounds
KR100263428B1 (ko) * 1992-10-28 2000-11-01 나카노 가쓰히코 신규한1,2-벤조이속사졸유도체또는그의염,및이를포함하는뇌보호제
GB9304500D0 (en) * 1993-03-05 1993-04-21 Glaxo Spa Heterocyclic compounds
GB9321221D0 (en) * 1993-10-14 1993-12-01 Glaxo Spa Heterocyclic compounds
ATE253057T1 (de) * 1994-08-30 2003-11-15 Sankyo Co Isoxazole
US5484763A (en) * 1995-02-10 1996-01-16 American Cyanamid Company Substituted benzisoxazole and benzisothiazole herbicidal agents
GB9502695D0 (en) * 1995-02-11 1995-03-29 Glaxo Spa Pharmaceutical composition
JPH11503445A (ja) * 1995-04-10 1999-03-26 藤沢薬品工業株式会社 ｃＧＭＰ−ＰＤＥ阻害剤としてのインドール誘導体
US5620997A (en) * 1995-05-31 1997-04-15 Warner-Lambert Company Isothiazolones
US5859042A (en) * 1995-09-27 1999-01-12 Ono Pharmaceutical Co., Ltd. Five membered heterocyclic compounds
FR2753098B1 (fr) * 1996-09-06 1998-11-27 Sod Conseils Rech Applic Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene
US5922752A (en) * 1997-06-11 1999-07-13 Hoechst Marion Roussell, Inc. NMDA (n-methyl-d-aspartate) antagonists
GB9803228D0 (en) * 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6828460B2 (en) * 1999-03-22 2004-12-07 Pfizer Inc. Resorcinol derivatives
EP1391460A1 (en) 1999-09-30 2004-02-25 Pfizer Products Inc. Tricyclic pyrrolyl amides as glycogen phosphorylase inhibitors
EP1088824B1 (en) * 1999-09-30 2004-01-07 Pfizer Products Inc. Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors
DE19960917A1 (de) * 1999-12-17 2001-06-21 Bayer Ag Neue 3-Oxo-2,1-benzisoxazol-1(3H)-carboxamide zur Behandlung von ZNS-Erkrankungen
US6632417B2 (en) * 2000-03-07 2003-10-14 Chevron U.S.A. Inc. Process for preparing zeolites
TWI283575B (en) 2000-10-31 2007-07-11 Eisai Co Ltd Medicinal compositions for concomitant use as anticancer agent
US6372919B1 (en) * 2001-01-11 2002-04-16 Dov Pharmaceutical, Inc. (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as an anti-depressant agent
US20020123490A1 (en) * 2001-03-01 2002-09-05 Pfizer Inc. Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
WO2003000657A1 (fr) * 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Derives de diamine
US6603000B2 (en) * 2001-07-11 2003-08-05 Boehringer Ingelheim Pharmaceuticals, Inc. Synthesis for heteroarylamine compounds
US7045543B2 (en) * 2001-11-05 2006-05-16 Enzrel Inc. Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
US20030162825A1 (en) * 2001-11-09 2003-08-28 Sepracor Inc. D-amino acid oxidase inhibitors for learning and memory
US6780891B2 (en) * 2001-11-30 2004-08-24 Sepracor Inc. Tramadol analogs and uses thereof
US6995144B2 (en) * 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
WO2004011459A1 (ja) 2002-07-31 2004-02-05 Mercian Corporation 新規生理活性物質
ATE325125T1 (de) 2002-09-06 2006-06-15 Janssen Pharmaceutica Nv Thienopyrrolyl und furanopyrrolyl verbindungen und deren verwendung als histamin h4 rezeptor liganden
KR101067045B1 (ko) * 2002-09-16 2011-09-22 선오비온 파마슈티컬스 인코포레이티드 트랜스 ４－（３，４－디클로로페닐）－１，２，３，４－테트라하이드로－１－나프탈렌아민을 사용한 ｃｎｓ 장애의 치료
US20040106681A1 (en) * 2002-10-03 2004-06-03 Cypress Bioscience, Inc. Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
AU2004207731B2 (en) * 2003-01-31 2009-08-13 Sanwa Kagaku Kenkyusho Co., Ltd. Compound inhibiting dipeptidyl peptidase iv
EP1633709A1 (en) * 2003-04-30 2006-03-15 Pfizer Products Inc. Anti-diabetic agents
US7442804B2 (en) 2003-07-07 2008-10-28 Ciba Specialty Chemicals Corporation Process for the preparation of furopyrroles
US7396940B2 (en) * 2003-10-23 2008-07-08 Hoffmann-La Roche Inc. Combinatorial library of 3-aryl-1H-indole-2-carboxylic acid
BRPI0417910A (pt) * 2003-12-29 2007-04-10 Sepracor Inc composto ou um sal ou salvato farmaceuticamente aceitáveis do mesmo, e, uso de um composto
ZA200605383B (en) * 2003-12-29 2008-06-25 Sepracor Inc Pyrrole and pyrazole daao inhibitors
RU2376309C2 (ru) 2004-07-01 2009-12-20 Асубио Фарма Ко., Лтд. Производное тиенопиразола, имеющее ингибирующую фосфодиэстеразу 7 (pde 7) активность
US7276631B2 (en) * 2004-07-20 2007-10-02 Bristol-Myers Squibb Company Cyclopentylamine and cyclohexylamine derivatives as NK-1/SSRI antagonists
CA2594665A1 (en) 2005-01-19 2006-07-27 Biolipox Ab Thienopyrroles useful in the treatment of inflammation
JP2009511462A (ja) 2005-10-06 2009-03-19 メルク シャープ エンド ドーム リミテッド Ｄ−アミノ酸酸化酵素阻害剤として神経変性および精神疾患を治療するための縮合ピロールカルボン酸の使用
UA95788C2 (en) * 2005-12-15 2011-09-12 Ф. Хоффманн-Ля Рош Аг Fused pyrrole derivatives
WO2007081542A2 (en) * 2006-01-06 2007-07-19 Sepracor Inc. Tetralone-based monoamine reuptake inhibitors
RU2430913C2 (ru) * 2006-01-06 2011-10-10 Сепракор Инк. Циклоалкиламины в качестве ингибиторов повторного поглощения моноамина
DK2013835T3 (en) * 2006-03-31 2015-12-14 Sunovion Pharmaceuticals Inc Preparation of chiral amides and AMINES
US20080058395A1 (en) * 2006-06-30 2008-03-06 Sepracor Inc. Fused heterocyclic inhibitors of D-amino acid oxidase
JP2009542683A (ja) * 2006-06-30 2009-12-03 セプラコア インコーポレーテッド Ｄ−アミノ酸オキシダーゼの縮合ヘテロ環式阻害剤
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
CA2676432A1 (en) * 2007-01-18 2008-07-24 Sepracor, Inc. Inhibitors of d-amino acid oxidase
BRPI0811639A2 (pt) * 2007-05-31 2014-09-30 Sepracor Inc Cicloaquilaminas fenil substituídas como inibidores da recaptação de monoamina
US20100120740A1 (en) * 2008-08-07 2010-05-13 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase

Also Published As

Publication number Publication date
AU2008284086A1 (en) 2009-02-12
RU2010107684A (ru) 2011-09-10
US20080004328A1 (en) 2008-01-03
WO2009020814A3 (en) 2009-12-30
CN101820760A (zh) 2010-09-01
JP2010535783A (ja) 2010-11-25
EP2173170A4 (en) 2010-12-08
WO2009020814A2 (en) 2009-02-12
KR20100047276A (ko) 2010-05-07
US7579370B2 (en) 2009-08-25
EP2173170A2 (en) 2010-04-14
BRPI0815077A2 (pt) 2014-09-30
CA2695431A1 (en) 2009-02-12
US20100022612A1 (en) 2010-01-28
US20100029741A1 (en) 2010-02-04

Similar Documents

Publication Publication Date Title
MX2010001196A (es) Heterociclicos fusionados.
MX2010012199A (es) Compuesto de cromeno.
DE602006015658D1 (de) Entzündungshemmende arylnitrilverbindungen
PH12014500760A1 (en) Mesoionic pesticides
TW200626559A (en) Anilino-pyrimidine analogs
MY141255A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
MX2009007077A (es) Analogos de ciclopamina.
TN2009000024A1 (en) Prodrug of cinnamide compound
WO2004072168A3 (en) Resin compositions
IN2014CN00613A (es)
TW200643067A (en) Surface modifier
HK1164114A1 (en) Antidepressant containing heterocyclic compound having specific structure
MY158520A (en) Tricyclic oxazolidinone antibiotic compounds
WO2007019191A3 (en) Thiazolopyrimidine kinase inhibitors
MY159183A (en) 5-amino-2-(1-hydroxy-ethyl)-tetrahydropyran derivatives
UA95922C2 (en) Glucuronate salt of a piperazine compound
WO2008099914A1 (ja) 蛍光プローブ
MX2010001344A (es) Compuesto de acido fenilacetico.
SG165361A1 (en) Antituberculous composition comprising oxazole compounds
AU7824900A (en) Compounds and methods for inhibiting mrp1
GB201115158D0 (en) Improvements in and realating to biocidal compositions
WO2007082262A3 (en) Novel compounds
MY160882A (en) Biocidal composition and method
WO2008140103A1 (ja) 反応硬化性接着性組成物および歯科用接着材キット
IN2015KN00276A (es)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal